Sparstolonin B

Sparstolonin B is a bioactive stilbene compound isolated from Sparganium stoloniferum, a traditional Chinese medicinal plant, that exerts anti-inflammatory and anticancer effects primarily by inhibiting Toll-like receptor (TLR) signaling pathways and suppressing NF-κB activation. Laboratory evidence indicates it can induce G2/M cell cycle arrest and trigger apoptosis in cancer cell lines through modulation of cyclin-dependent kinase activity and pro-apoptotic protein expression.

Origin & History

Sparstolonin B (SsnB) is a naturally occurring isocoumarin compound isolated from the tubers and rhizomes of Sparganium stoloniferum, a perennial aquatic herb native to North and East China. The compound has been purified and characterized through X-ray crystallography and nuclear magnetic resonance spectroscopy, and has been successfully synthesized through chemical routes achieving 38-40% overall yield.

Historical & Cultural Context

In traditional Chinese medicine, Sparganium stoloniferum has been used to regulate menstruation, promote milk production (galactosis), and induce muscle relaxation (spasmolysis). The plant's rhizomes and tubers form the basis of these traditional applications, though specific historical preparation methods are not extensively documented.

Health Benefits

• Anti-inflammatory effects demonstrated in laboratory cell culture studies (preliminary evidence only)
• Cancer cell growth inhibition shown in neuroblastoma and prostate cancer cell lines (in vitro evidence only)
• Cell cycle arrest and apoptosis induction in cancer cells (laboratory studies only)
• Potential antioxidant properties affecting oxidative stress markers (mechanistic studies only)
• Modulation of cellular signaling pathways involved in cell proliferation (preliminary in vitro evidence)

How It Works

Sparstolonin B selectively inhibits Toll-like receptor 2 (TLR2) and TLR4 co-receptor signaling by disrupting lipid raft integrity, thereby suppressing downstream MyD88-dependent NF-κB and MAPK pathway activation and reducing pro-inflammatory cytokine production including TNF-α and IL-6. In cancer cell models, it downregulates cyclin B1 and CDC2 expression to induce G2/M cell cycle arrest while upregulating the pro-apoptotic proteins Bax and cleaved caspase-3, and downregulating anti-apoptotic Bcl-2. Some evidence suggests it also inhibits PI3K/Akt signaling, further contributing to its antiproliferative effects in neuroblastoma and prostate cancer cell lines.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses of Sparstolonin B have been conducted. All available evidence comes exclusively from in vitro cell culture studies and laboratory research focusing on cellular mechanisms in cancer cell lines and endothelial cells.

Clinical Summary

All current evidence for Sparstolonin B derives exclusively from in vitro cell culture studies and preclinical laboratory models; no human clinical trials have been conducted as of 2024. In neuroblastoma cell line studies, Sparstolonin B reduced cell viability in a dose-dependent manner with IC50 values reported in the low micromolar range (approximately 10–50 µM depending on cell line). Prostate cancer cell line experiments demonstrated significant apoptosis induction and cell cycle arrest at similar concentrations, though these doses have not been validated in animal or human models. The complete absence of pharmacokinetic, bioavailability, and toxicology data in humans means efficacy and safety claims cannot be substantiated beyond preliminary mechanistic observations.

Nutritional Profile

Sparstolonin B (SsnB) is a purified bioactive isocoumarin compound isolated from Sparganium stoloniferum (a traditional Chinese medicinal herb), not a conventional food ingredient and therefore has no macronutrient, micronutrient, fiber, or caloric profile. As a small-molecule phytochemical with a molecular weight of approximately 338.35 g/mol and molecular formula C18H18O7, it is classified strictly as a bioactive secondary metabolite. Typical experimental concentrations used in laboratory studies range from 1–100 μM in cell culture systems. It exhibits lipophilic characteristics due to its isocoumarin scaffold, suggesting moderate membrane permeability and potential for oral bioavailability, though formal pharmacokinetic data in humans is not yet established. No vitamin, mineral, protein, fat, or carbohydrate content is applicable. Known bioactive properties center on its Toll-like receptor (TLR2 and TLR4) antagonist activity, selectively blocking lipopolysaccharide- and lipoteichoic acid-induced inflammatory signaling pathways. Antioxidant activity has been mechanistically linked to modulation of reactive oxygen species (ROS) pathways in vitro. Bioavailability data in humans is absent; animal model studies suggest hepatic first-pass metabolism is likely, but specific metabolite profiles have not been fully characterized in peer-reviewed literature as of early 2025.

Preparation & Dosage

No clinically studied dosage ranges are available as human clinical trials have not been conducted. Laboratory studies have used varying concentrations dissolved in DMSO, but these cannot be translated to therapeutic human dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Green Tea Extract, Resveratrol, Quercetin, Boswellia

Safety & Interactions

No human safety data, established dosage guidelines, or toxicology profiles exist for Sparstolonin B, as it has not been evaluated in clinical trials or formal human pharmacokinetic studies. Because it inhibits TLR-mediated immune signaling and NF-κB activation, theoretical interactions with immunosuppressant drugs (e.g., corticosteroids, tacrolimus) and anti-inflammatory medications are plausible and warrant caution. Pregnant and breastfeeding individuals should avoid Sparstolonin B entirely given the complete absence of safety data in these populations. Anyone considering experimental use should consult a qualified healthcare provider, particularly those on anticoagulants or chemotherapy agents, as interactions cannot be ruled out.